International Journal For Multidisciplinary Research
E-ISSN: 2582-2160
•
Impact Factor: 9.24
A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal
Home
Research Paper
Submit Research Paper
Publication Guidelines
Publication Charges
Upload Documents
Track Status / Pay Fees / Download Publication Certi.
Editors & Reviewers
View All
Join as a Reviewer
Reviewer Referral Program
Get Membership Certificate
Current Issue
Publication Archive
Conference
Publishing Conf. with IJFMR
Upcoming Conference(s) ↓
WSMCDD-2025
GSMCDD-2025
Conferences Published ↓
RBS:RH-COVID-19 (2023)
ICMRS'23
PIPRDA-2023
Contact Us
Plagiarism is checked by the leading plagiarism checker
Call for Paper
Volume 6 Issue 6
November-December 2024
Indexing Partners
Comparative Efficacy and Safety of TNF-Alpha Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Systematic Review
Author(s) | Akaash Parthasarathi, Donald D. Savariah, Sachin Marodia, Shahpoor A. Shirzada |
---|---|
Country | India |
Abstract | Psoriasis is a chronic inflammatory skin disease that significantly impacts patients' quality of life. The advent of biological therapies has revolutionized the treatment landscape for moderate to severe psoriasis, offering targeted mechanisms of action with higher efficacy and improved safety profiles compared to traditional systemic treatments. This systematic review aims to evaluate and compare the efficacy and safety of three major classes of biologics: TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors. We conducted a comprehensive search of PubMed, MEDLINE, and Cochrane Library databases for randomized controlled trials (RCTs) and observational studies published between 2015 and 2023. A total of 30 studies involving over 15,000 patients were included. The primary outcomes assessed were the Psoriasis Area and Severity Index (PASI) 75, 90, and 100 response rates and safety profiles. IL-23 inhibitors demonstrated the highest efficacy, with superior PASI 90 and PASI 100 responses, followed by IL-17 inhibitors. TNF-alpha inhibitors, while effective, showed lower PASI 90 and PASI 100 response rates but had a well-established long-term safety profile. IL-17 inhibitors were associated with higher rates of candidiasis, while IL-23 inhibitors had fewer adverse events overall. This review supports the use of IL-23 inhibitors as the most effective biological therapy for moderate to severe psoriasis, with IL-17 inhibitors as a strong alternative. TNF-alpha inhibitors remain a viable option, particularly for patients with comorbid conditions where their safety profile is well-documented. |
Keywords | TNF-Alpha Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors , Psoriasis |
Field | Medical / Pharmacy |
Published In | Volume 6, Issue 6, November-December 2024 |
Published On | 2024-11-05 |
Cite This | Comparative Efficacy and Safety of TNF-Alpha Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Systematic Review - Akaash Parthasarathi, Donald D. Savariah, Sachin Marodia, Shahpoor A. Shirzada - IJFMR Volume 6, Issue 6, November-December 2024. |
Share this
E-ISSN 2582-2160
doi
CrossRef DOI is assigned to each research paper published in our journal.
IJFMR DOI prefix is
10.36948/ijfmr
Downloads
All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.